Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709918 | 0.93 | GRIK1 (0.38) | GRIK1LMNAMAPTGRM5PDE5A | |
| SCHEMBL6710289 | 0.92 | GRIK1 (0.36) | GRIK1LMNAMAPTAKR1C2AKR1C1 | |
| SCHEMBL6710044 | 0.91 | GRIK1 (0.36) | TP53TSHRGRIK1LMNAMAPT | |
| SCHEMBL6709189 | 0.91 | GRIK1 (0.39) | TP53TSHRGRIK1LMNAMAPT | |
| SCHEMBL6710160 | 0.89 | TP53 (0.36) | TP53TSHRLMNAMAPTCNR2 | |
| SCHEMBL6708956 | 0.89 | LRRK2 (0.38) | GRIK1LMNAMAPT | |
| SCHEMBL6713672 | 0.88 | GRIK1 (0.36) | TP53TSHRGRIK1LMNAMAPT | |
| SCHEMBL6711788 | 0.88 | KDM1A (0.36) | GRIK1LMNAMAPTGRM5CNR2 | |
| SCHEMBL6710032 | 0.87 | GRIK1 (0.36) | GRIK1LMNAMAPTGRM5 | |
| SCHEMBL6710035 | 0.87 | GRIK1 (0.36) | GRIK1LMNAMAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | TP53 2699/4885TSHR 3901/4885GRIK1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.